{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:28:38Z","timestamp":1740133718605,"version":"3.37.3"},"reference-count":50,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Daclatasvir (DCV) is a first-in-class hepatitis C virus (HCV) nonstructural 5A replication complex inhibitor (NS5A RCI) that is clinically effective in interferon-free combinations with direct-acting antivirals (DAAs) targeting alternate HCV proteins. Recently, we reported NS5A RCI combinations that enhance HCV inhibitory potential\n            <jats:italic>in vitro<\/jats:italic>\n            , defining a new class of HCV inhibitors termed NS5A synergists (J. Sun, D. R. O\u2019Boyle II, R. A. Fridell, D. R. Langley, C. Wang, S. Roberts, P. Nower, B. M. Johnson F. Moulin, M. J. Nophsker, Y. Wang, M. Liu, K. Rigat, Y. Tu, P. Hewawasam, J. Kadow, N. A. Meanwell, M. Cockett, J. A. Lemm, M. Kramer, M. Belema, and M. Gao, Nature 527:245\u2013248, 2015, doi:\n            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1038\/nature15711\">10.1038\/nature15711<\/jats:ext-link>\n            ). To extend the characterization of NS5A synergists, we tested new combinations of DCV and NS5A synergists against genotype (gt) 1 to 6 replicons and gt 1a, 2a, and 3a viruses. The kinetics of inhibition in HCV-infected cells treated with DCV, an NS5A synergist (NS5A-Syn), or a combination of DCV and NS5A-Syn were distinctive. Similar to activity observed clinically, DCV caused a multilog drop in HCV, followed by rebound due to the emergence of resistance. DCV\u2013NS5A-Syn combinations were highly efficient at clearing cells of viruses, in line with the trend seen in replicon studies. The retreatment of resistant viruses that emerged using DCV monotherapy with DCV\u2013NS5A-Syn resulted in a multilog drop and rebound in HCV similar to the initial decline and rebound observed with DCV alone on wild-type (WT) virus. A triple combination of DCV, NS5A-Syn, and a DAA targeting the NS3 or NS5B protein cleared the cells of viruses that are highly resistant to DCV. Our data support the observation that the cooperative interaction of DCV and NS5A-Syn potentiates both the genotype coverage and resistance barrier of DCV, offering an additional DAA option for combination therapy and tools for explorations of NS5A function.\n          <\/jats:p>","DOI":"10.1128\/aac.02639-15","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T03:23:15Z","timestamp":1451359395000},"page":"1573-1583","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Synergistic Activity of Combined NS5A Inhibitors"],"prefix":"10.1128","volume":"60","author":[{"suffix":"II","given":"Donald R.","family":"O'Boyle","sequence":"first","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Nower","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fridell","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyasena","family":"Hewawasam","sequence":"additional","affiliation":[{"name":"Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Meanwell","sequence":"additional","affiliation":[{"name":"Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makonen","family":"Belema","sequence":"additional","affiliation":[{"name":"Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan B.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Cockett","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hua","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02164-12"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.11.009"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02788-14"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/510043a"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S79584"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.06.032"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep04765"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122844"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00215-11"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.03.026"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.019"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.024"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.376822"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.054569-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1021\/ci400631n"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03580"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2456"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-394-3_7"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm501291c"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02352-08"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15711"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02861-12"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-11"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05977-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.04.024"},{"key":"e_1_3_2_28_2","unstructured":"Hewawasam P Kadow JF Lopez OD Meanwell NA Tu Y Wang AX Xu N Gupta SVSVK Srinivasu P Kumar IG Kumar PS Belema M Fridell RA Gao M Lemm JA O'Boyle DR II Sun J Wang C Wang Y. July 2013. Hepatitis C virus inhibitors. US Patent 20130183269 A1."},{"key":"e_1_3_2_29_2","unstructured":"Sun J Gao M O'Boyle DR II Lemm JA Roberts SB Belema M Meanwell NA. June 2013. Methods to identify combinations of NS5a targeting compound that act synergistically to inhibit hepatitis C virus replication. US patent 20130157894 A1."},{"key":"e_1_3_2_30_2","unstructured":"Bristol-Myers Squibb. 8 November 2014. Phase 3 UNITY trials demonstrate high cure rates for investigational all-oral daclatasvir TRIO fixed-dose combination in genotype 1 hepatitis C patients including those with cirrhosis. Press release. http:\/\/news.bms.com\/press-release\/rd-news\/phase-3-unity-trials-demonstrate-high-cure-rates-investigational-all-oral-dacl."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24594"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-10"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12646"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02495-13"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01186-12"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61225-3"},{"key":"e_1_3_2_37_2","volume-title":"Discovery and evaluation of GW0385, a third-generation HIV protease inhibitor: broad spectrum inhibition of wild-type and multi-PI-resistant viruses by femtomolar HIV protease inhibitors","author":"Spaltenstein A","year":"2003","unstructured":"Spaltenstein A, Andrews W, Furfine E, Hazen R, Hale M, Hanlon M, Kaldor I, Miller J, Samano V, Ray J, Xu R. 2003. Discovery and evaluation of GW0385, a third-generation HIV protease inhibitor: broad spectrum inhibition of wild-type and multi-PI-resistant viruses by femtomolar HIV protease inhibitors. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, 13 to 16 July 2003, Paris, France."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1039\/c2np00065b"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06169-11"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2014.00009"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002630"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.08.035"},{"key":"e_1_3_2_43_2","first-page":"267","volume-title":"Hepatitis C viruses: genomes and molecular biology","author":"He Y","unstructured":"He Y, Staschke KA, Tan SL. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication, p 267\u2013292. In Tan SL (ed), Hepatitis C viruses: genomes and molecular biology. Horizon Bioscience, Norfolk, United Kingdom."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00753-07"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/\/journal.ppat.1001220"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407787200"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004064"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02630-12"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00054-12"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.08.014"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml300090x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02639-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02639-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:36:00Z","timestamp":1645475760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02639-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1128\/AAC.02639-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02639-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"2015-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}